Nanobiotix Files September 2025 6-K Report

Ticker: NBTX · Form: 6-K · Filed: Sep 17, 2025 · CIK: 1760854

Sentiment: neutral

Topics: sec-filing, 6-K, compliance

TL;DR

Nanobiotix (NBTX) filed its monthly 6-K report on 9/17/25, confirming it files 20-F annually.

AI Summary

Nanobiotix S.A. filed a Form 6-K on September 17, 2025, to report its activities for the month of September 2025. The company, based in Paris, France, is a pharmaceutical preparations company and is submitting this report under the 1934 Securities Exchange Act. Nanobiotix S.A. is also filing its annual report under cover of Form 20-F.

Why It Matters

This filing provides an update on Nanobiotix S.A.'s ongoing activities and compliance with SEC reporting requirements for foreign private issuers.

Risk Assessment

Risk Level: low — This filing is a routine report of foreign private issuer activities and does not contain new financial or operational information that would typically increase risk.

Key Numbers

Key Players & Entities

FAQ

What is the purpose of a Form 6-K filing?

A Form 6-K is a report of foreign private issuers required to be filed with the SEC to provide information that the issuer makes or is required to make public pursuant to the laws of its home country, or that it furnishes or is required to furnish to its security holders.

What is Nanobiotix S.A.'s primary business?

Nanobiotix S.A. is in the business of pharmaceutical preparations, as indicated by its SIC code 2834.

When was this Form 6-K filed?

This Form 6-K was filed on September 17, 2025.

Does Nanobiotix S.A. file annual reports?

Yes, Nanobiotix S.A. indicates it files annual reports under cover of Form 20-F.

Where is Nanobiotix S.A. headquartered?

Nanobiotix S.A. is headquartered at 60 Rue de Wattignies, 75012 Paris, France.

Filing Stats: 172 words · 1 min read · ~1 pages · Grade level 9.1 · Accepted 2025-09-17 16:43:24

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Nanobiotix S.A. (Registrant) Date: September 17, 2025 /s/ Bart Van Rhijn Bart Van Rhijn Chief Financial Officer

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing